# VWC2

## Overview
VWC2, or von Willebrand factor C domain containing 2, is a gene that encodes a protein involved in the regulation of bone formation and cellular signaling. The protein, also referred to as Brorin, is categorized as an extracellular modulator due to its role in interacting with signaling molecules outside the cell. VWC2 is primarily expressed in osteoblasts, where it plays a crucial role in the early stages of biomineralization by antagonizing activin A signaling, a member of the transforming growth factor (TGF)-β superfamily. This interaction is significant as it modulates the activin-Smad2 signaling pathway, thereby influencing osteoblast differentiation and mineralization processes. Through its binding to activin A, VWC2 effectively regulates bone formation and regeneration, highlighting its importance in bone biology (Almehmadi2018VWC2).

## Function
VWC2, also known as Brorin, is a gene that encodes a protein involved in bone formation and cellular signaling. The VWC2 protein is expressed in osteoblasts, with its expression peaking during the early stages of biomineralization. It is localized at the bone surface and within bone matrix-embedded osteocytes (Almehmadi2018VWC2). Functionally, VWC2 acts as an antagonist to activin A signaling in osteoblasts. Activin A typically induces Smad2 phosphorylation, a process involved in signal transduction, but VWC2 inhibits this phosphorylation in a dose-dependent manner. This suggests that VWC2 modulates activin signaling pathways, influencing bone formation and regeneration (Almehmadi2018VWC2).

VWC2 specifically binds to activin members, particularly the βA subunit isoform of activin, which is abundant in bone. This binding inhibits activin A-induced osteoblast cell growth and differentiation, counteracting the effects of activin A, such as the down-regulation of osteogenic markers like Osx and the upregulation of Col1a2. VWC2 enhances osteoblast mineralization, which is otherwise inhibited by activin A, promoting bone formation by inhibiting the Activin-Smad2 signaling pathway (Almehmadi2018VWC2).

## Interactions
VWC2 (von Willebrand factor C domain containing 2) is known to interact with activin A, a member of the transforming growth factor (TGF)-β superfamily. VWC2 acts as an antagonist to activin A by directly binding to it, which inhibits activin A-induced Smad2 phosphorylation in osteoblasts. This interaction is significant because it modulates activin signaling pathways that are crucial for bone formation. The binding of VWC2 to activin A occurs in a dose-dependent manner, suggesting that VWC2 can effectively regulate the bioactivity of activin A in bone biology (Almehmadi2018VWC2).

VWC2 specifically binds to the βA and βB subunit isoforms of activin, with a stronger interaction observed with the βA subunit. This binding was confirmed through immunoprecipitation and Western blot analysis, demonstrating that VWC2 is a direct binding partner of mature activin A, which is a homodimer of the βA subunit (Almehmadi2018VWC2). These interactions highlight VWC2's role as an extracellular modulator in the TGF-β signaling pathway, particularly in the context of bone formation and mineralization processes (Almehmadi2018VWC2).


## References


[1. (Almehmadi2018VWC2) Ahmad Almehmadi, Yoshio Ohyama, Masaru Kaku, Ahmed Alamoudi, Dina Husein, Michitsuna Katafuchi, Yuji Mishina, and Yoshiyuki Mochida. Vwc2 increases bone formation through inhibiting activin signaling. Calcified Tissue International, 103(6):663–674, August 2018. URL: http://dx.doi.org/10.1007/s00223-018-0462-9, doi:10.1007/s00223-018-0462-9. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00223-018-0462-9)